On Friday, Shares of Becton Dickinson and Co (NYSE:BDX), gained 3.21% to $154.81.
BD (Becton, Dickinson and Company), will present its combined, strengthened solutions together as one company, at the 50th Annual American Society of Health-system Pharmacists (ASHP) Midyear Clinical Meeting being held Dec. 6-10 in New Orleans.
BD will display a comprehensive portfolio of medication administration solutions at the Ernest N. Morial Convention Center, booth #2339. From IV preparation in the pharmacy to administration at the bedside, medication dispensing and automation in expanding care settings, and enterprise monitoring to supporting care for population health administration, booth attendees will receive a hands-on demonstration of the broader and deeper suite of solutions designed to assist improve the safety and cost of healthcare.
“The combined representation of BD and CareFusion during this year’s ASHP meeting exemplifies a noteworthy journey in the transformation of how we provide more advanced solutions for the many challenges concerning medication administration,” said Tom Polen, executive vice president at BD and president of BD’s Medical Segment. “BD is now even better positioned to address the challenges in medication administration with our extensive and strengthened solutions. Our expanded portfolio being displayed at ASHP will provide a firsthand experience of the value our connected offerings bring to patients and health care workers.”
Becton, Dickinson and Company develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment offers syringes and pen needles for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; generic prefilled injectables; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply administration systems; prefillable drug delivery systems; respiratory ventilation, and diagnostics equipment and consumables; and consumables for patient monitoring and anesthesia delivery.
Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), inclined 1.77% to $95.32, during its last trading session.
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind fund managers and investors that they have until December 21, 2015 to file lead plaintiff applications in a securities class action lawsuit against Valeant Pharmaceuticals International, Inc. (VRX) if they purchased the Company’s securities between February 28, 2014 through October 21, 2015, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Finally, Shares of Halliburton Company (NYSE:HAL), ended its last trade with -0.29% loss, and closed at $37.89.
Halliburton, declared that it will present at the Wells Fargo 2015 Energy Symposium on Wednesday, December 9, 2015, at 7:00 a.m. Central time (8:00 a.m. Eastern time).
Halliburton Company provides a range of services and products to the upstream oil and natural gas industry worldwide. The company operates through two segments, Completion and Production, and Drilling and Evaluation.
